|
|||||
|
|

Behavioral health company Acadia Healthcare (NASDAQ:ACHC) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.2% year on year to $869.2 million. The company expects the full year’s revenue to be around $3.33 billion, close to analysts’ estimates. Its non-GAAP profit of $0.83 per share was 17.4% above analysts’ consensus estimates.
Is now the time to buy ACHC? Find out in our full research report (it’s free).
Acadia Healthcare’s second quarter saw revenue and adjusted profit beat Wall Street expectations, but market reaction was sharply negative due to declining margins and cautious management commentary on Medicaid volumes. CEO Christopher Hunter cited weaker Medicaid volumes in acute care and ongoing challenges at underperforming facilities as key headwinds. He explained, “The primary driver of volume coming in below our expectations really was the weaker Medicaid volumes in our acute care business.” Management acknowledged that local market pressures and evolving utilization patterns among managed Medicaid plans contributed to the softness.
Looking ahead, Acadia Healthcare’s updated guidance reflects management’s caution around softer volumes, higher start-up costs, and continued uncertainty in the Medicaid landscape. CFO Heather Dixon pointed to a pull-forward of start-up losses due to accelerated facility openings, adding, “We are experiencing those incremental start-up costs earlier in the year than what we would have previously anticipated.” Management also flagged policy changes such as the One Big Beautiful Bill Act and evolving payer dynamics as factors that could influence growth, with a focus on mitigating risk through disciplined capital allocation and operational adjustments.
Management attributed the quarter’s performance to a combination of robust growth in commercial and Medicare volumes, headwinds in Medicaid patient volume, and higher costs associated with rapid facility expansion.
Acadia’s revised outlook emphasizes cautious volume growth, increased start-up costs, and policy-driven supplemental payments as the primary drivers of its forward guidance.
In the coming quarters, our analysts will focus on (1) the trajectory of Medicaid volumes and any further changes in payer authorization practices, (2) the pace and profitability of newly added beds as they ramp up, and (3) the impact of policy-driven supplemental payments, including potential adjustments stemming from the One Big Beautiful Bill Act. Progress on capital allocation discipline and cost management will also be key signposts for Acadia’s operational resilience.
Acadia Healthcare currently trades at $20.40, down from $21.79 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| 7 hours | |
| 9 hours | |
| Nov-06 | |
| Nov-05 | |
| Nov-05 | |
| Nov-05 | |
| Nov-05 | |
| Nov-03 | |
| Oct-29 | |
| Oct-28 | |
| Oct-20 | |
| Oct-08 | |
| Oct-08 | |
| Oct-07 | |
| Oct-06 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite